In recent years, the advent and expanding use of injectable GLP-1 receptor agonists have revolutionized the management of obesity and type 2 diabetes, offering unprecedented efficacy in weight reduction and glycemic control. Among these agents, semaglutide and tirzepatide have emerged as frontrunners, heralded for their potent anorectic and metabolic effects. However, a significant clinical question looms large: what transpires when patients discontinue these medications in real-world scenarios? Do they experience substantial weight regain, or are their therapeutic gains maintained through alternative interventions and lifestyle adjustments?
A large-scale, retrospective cohort study conducted at Cleveland Clinic brings fresh insights into this pivotal issue. Analyzing data from close to 8,000 adult patients with obesity or overweight in Ohio and Florida who ceased semaglutide or tirzepatide treatment between three and twelve months after initiation, the research team sought to elucidate weight trajectories and subsequent treatment pathways post-discontinuation. This investigation represents one of the most extensive real-world analyses exploring the durability of obesity treatment effects outside the controlled environments of randomized clinical trials.
The findings of this robust analysis challenge prior conceptions rooted in clinical trials, which suggested that cessation of semaglutide or tirzepatide often precipitates rapid weight regain, with patients recouping over half the weight lost within a year. Contrary to these reports, the Cleveland Clinic data reveal that average weight regain post-discontinuation is strikingly modest. Notably, patients enrolled for obesity management lost approximately 8.4% of their body weight before stopping the medication and regained only about 0.5% on average after twelve months. This divergence underscores the complex interplay of treatment adherence, healthcare access, and behavioral factors influencing long-term outcomes in everyday clinical practice.
Delving deeper, the cohort comprising individuals treated for type 2 diabetes exhibited even more favorable results, with an average initial weight loss of 4.4% and an additional 1.3% weight reduction observed one year following medication discontinuation. Such results may be partly attributable to differing patterns of insurance coverage and healthcare utilization between diabetic and obese patient populations, influencing medication adherence and continuation rates.
Indeed, the study highlights noteworthy heterogeneity at the individual level, with 55% of patients in the obesity group regaining weight in the year following discontinuation, while 45% either maintained or continued to lose weight. In the diabetes subgroup, the proportions shifted slightly, with 44% experiencing weight gain and 56% maintaining or further decreasing body weight. These nuances underscore the critical need for personalized therapeutic strategies and continuous patient engagement beyond pharmacological treatment.
Further examination of patients’ subsequent therapeutic decisions revealed that discontinuation often does not equate to abandonment of weight management efforts. A considerable fraction, approximately 27%, transitioned to alternative pharmacotherapies, including older-generation obesity drugs or switched between semaglutide and tirzepatide, highlighting the dynamic landscape of obesity pharmacotherapy. Additionally, 20% of patients recommenced their original GLP-1 receptor agonist, a phenomenon more pronounced among those with type 2 diabetes, likely reflecting more consistent insurance coverage and perceived necessity in glycemic control.
Beyond medications, nearly 14% of participants engaged in structured lifestyle interventions, consulting with dietitians, exercise specialists, or other healthcare professionals to sustain weight loss efforts. This integrative approach aligns with contemporary obesity management paradigms, emphasizing multimodal treatment modalities encompassing behavioral, nutritional, and physical activity components. Remarkably, less than 1% of the cohort pursued metabolic and bariatric surgery, indicating a preference for non-surgical approaches or potential barriers to surgical access.
Exploring the reasons for medication discontinuation, prior research by the same group identified cost and insurance limitations as the predominant drivers, overshadowing side effects as a less frequent cause. Such economic and policy-related barriers elucidate disparities in treatment continuity, potentially influencing long-term outcomes. The fact that patients with type 2 diabetes were more frequently able to restart therapy may reflect more favorable insurance provisions for diabetes medications compared to those indicated primarily for obesity.
From a mechanistic standpoint, the pharmacodynamics of GLP-1 receptor agonists underpin their efficacy in promoting satiety, delaying gastric emptying, and enhancing insulin secretion. However, upon withdrawal, the body’s homeostatic mechanisms often strive to re-establish prior weight set points. The real-world data suggesting attenuated weight regain may thus result from patients adopting complementary strategies, such as alternative medications, behavioral modifications, or structured lifestyle changes, which collectively counteract physiological tendencies toward weight restoration.
The implications of this study extend beyond immediate clinical practice, underscoring the imperative of sustained, personalized support for patients navigating obesity treatment pathways. Medication discontinuation should not be perceived as therapeutic failure but rather as a juncture for re-evaluation and adaptation of treatment plans. This paradigm shift emphasizes the continuum of care necessary to achieve durable weight management, integrating pharmacological, behavioral, and psychosocial elements.
Dr. Hamlet Gasoyan, Ph.D., MPH, leading the research at the Center for Value-Based Care Research at Cleveland Clinic, emphasizes that the journey to obesity management is often non-linear. Patients frequently cycle through various therapies reflective of insurance coverage dynamics, side effect profiles, personal preferences, and evolving medical advice. These findings encourage clinicians to foster open dialogues and develop flexible treatment regimens tailored to individual circumstances.
Looking forward, Dr. Gasoyan and colleagues aim to delve deeper into assessing the comparative effectiveness of alternative obesity treatments in patients who discontinue semaglutide or tirzepatide. Such investigations will be instrumental in guiding evidence-based decision-making and optimizing patient-centered care strategies.
This groundbreaking research, published in the peer-reviewed journal Diabetes, Obesity and Metabolism, provides an essential real-world complement to existing randomized trial data. It offers a nuanced understanding of the complexities inherent in obesity treatment, highlighting the resilience of patients’ weight control efforts post-GLP-1 receptor agonist discontinuation and the critical role of personalized, multifaceted approaches in sustaining metabolic health.
Subject of Research: Obesity treatment dynamics and weight changes following discontinuation of injectable GLP-1 receptor agonists semaglutide and tirzepatide in clinical practice.
Article Title: Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.
News Publication Date: March 12, 2026.
Web References:
– https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70660
– http://dx.doi.org/10.1111/dom.70660
Keywords: Obesity, Type 2 Diabetes, Semaglutide, Tirzepatide, GLP-1 Receptor Agonists, Weight Regain, Pharmacotherapy, Lifestyle Intervention, Insurance Coverage, Real-World Evidence, Metabolic Disorders, Bariatric Surgery.
